Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

How much influence should patients have in drug approval recommendations?

This article was originally published in Scrip

Executive Summary

Just how far should patients be involved in decision-making processes regarding new drug evaluations? It's a question that the European Medicines Agency is poring over as it looks at how best to match regulatory science to clinical needs, based partly on the views of those who are on the receiving end of innovation in medicine.

You may also be interested in...



What The Pandemic Can Teach Us About Running Clinical Trials

Participants in a recent webinar looked at how the coronavirus is changing the way we look at clinical trials and whether new EU COVID-19 guidance might hold lessons for future approaches to study design.

COVID-19: Global Agencies Step Up Focus On Real-World Data

There is much talk around the importance of clinical trials in finding new treatments and vaccines for COVID-19 patients, but observational studies in clinical practice also have a vital role to play, including the impact on pregnant women. 

First Drug Approved Under New Scheme To Speed Access In Poorer Countries

Switzerland’s medicines agency has cleared Ferring’s carbetocin for preventing uterine haemorrhage under the Marketing Authorization for Global Health Products (MAGHP) procedure, which is intended to accelerate the approval of new products in low- and middle-income countries. 

Topics

Related Companies

UsernamePublicRestriction

Register

PL220371

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel